The Present and Future of Optic Pathway Glioma Therapy.
Simone Dal BelloDeborah MartinuzziYan TereshkoDaniele VerittiValentina SaraoGian Luigi GigliPaolo LanzettaMariarosaria ValentePublished in: Cells (2023)
Optic pathway gliomas (OPGs) encompass two distinct categories: benign pediatric gliomas, which are characterized by favorable prognosis, and malignant adult gliomas, which are aggressive cancers associated with a poor outcome. Our review aims to explore the established standards of care for both types of tumors, highlight the emerging therapeutic strategies for OPG treatment, and propose potential alternative therapies that, while originally studied in a broader glioma context, may hold promise for OPGs pending further investigation. These potential therapies encompass immunotherapy approaches, molecular-targeted therapy, modulation of the tumor microenvironment, nanotechnologies, magnetic hyperthermia therapy, cyberKnife, cannabinoids, and the ketogenic diet. Restoring visual function is a significant challenge in cases where optic nerve damage has occurred due to the tumor or its therapeutic interventions. Numerous approaches, particularly those involving stem cells, are currently being investigated as potential facilitators of visual recovery in these patients.
Keyphrases
- optic nerve
- stem cells
- high grade
- optical coherence tomography
- end stage renal disease
- physical activity
- healthcare
- ejection fraction
- chronic kidney disease
- human health
- cell therapy
- prognostic factors
- risk assessment
- weight loss
- big data
- quality improvement
- smoking cessation
- replacement therapy
- patient reported
- simultaneous determination